These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 18388866)

  • 1. Emerging evidence of the impact of kidney disease on drug metabolism and transport.
    Nolin TD; Naud J; Leblond FA; Pichette V
    Clin Pharmacol Ther; 2008 Jun; 83(6):898-903. PubMed ID: 18388866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
    Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renal failure on drug transport and metabolism.
    Sun H; Frassetto L; Benet LZ
    Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered nonrenal drug clearance in ESRD.
    Nolin TD
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):555-9. PubMed ID: 18941346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current understanding of drug disposition in kidney disease.
    Naud J; Nolin TD; Leblond FA; Pichette V
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):10S-22S. PubMed ID: 22232747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic implications of renal anionic drug transporters.
    Masereeuw R; Russel FG
    Pharmacol Ther; 2010 May; 126(2):200-16. PubMed ID: 20227439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of chronic renal failure on drug metabolism and transport.
    Dreisbach AW
    Clin Pharmacol Ther; 2009 Nov; 86(5):553-6. PubMed ID: 19776735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.
    Miners JO; Yang X; Knights KM; Zhang L
    Clin Pharmacol Ther; 2017 Sep; 102(3):436-449. PubMed ID: 28599065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug therapy in impaired liver and kidney function].
    Galeazzi RL
    Schweiz Med Wochenschr; 1983 May; 113(20):726-32. PubMed ID: 6879125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug dosing adjustments in patients with chronic kidney disease.
    Munar MY; Singh H
    Am Fam Physician; 2007 May; 75(10):1487-96. PubMed ID: 17555141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments.
    Watanabe T; Maeda K; Kondo T; Nakayama H; Horita S; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2009 Jul; 37(7):1471-9. PubMed ID: 19364828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dosages of drugs in patients with kidney function disorders].
    Verresen L
    Ned Tijdschr Geneeskd; 1991 Mar; 135(13):547-51. PubMed ID: 2027403
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adjusting dosage of drugs in patients with kidney or liver failure].
    Krähenbühl S
    Schweiz Med Wochenschr; 1998 Feb; 128(6):189-94. PubMed ID: 9540139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.
    Shitara Y; Sato H; Sugiyama Y
    Annu Rev Pharmacol Toxicol; 2005; 45():689-723. PubMed ID: 15822193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Disease Pathologies on Transporter Expression and Function.
    Atilano-Roque A; Roda G; Fogueri U; Kiser JJ; Joy MS
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S205-21. PubMed ID: 27385176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Change in the pharmacokinetics of drug substances in kidney diseases].
    Kudrin AN; Davydova ON; Androsova SO
    Klin Med (Mosk); 1980 May; 58(5):13-6. PubMed ID: 6991802
    [No Abstract]   [Full Text] [Related]  

  • 17. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.
    Prokopienko AJ; Nolin TD
    Expert Rev Clin Pharmacol; 2018 Jan; 11(1):71-82. PubMed ID: 28905671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram for drug dosage in renal failure, based on mean plasma concentrations.
    Ash SR; Jacobi J
    Int J Artif Organs; 1983 May; 6(3):101-4. PubMed ID: 6874119
    [No Abstract]   [Full Text] [Related]  

  • 19. [Renal function and pharmacotherapy in children].
    Jovanović O
    Srp Arh Celok Lek; 1995 Jun; 123 Suppl 1():15-21. PubMed ID: 18193796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonrenal drug clearance in CKD: Searching for the path less traveled.
    Momper JD; Venkataramanan R; Nolin TD
    Adv Chronic Kidney Dis; 2010 Sep; 17(5):384-91. PubMed ID: 20727508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.